Acadia reports additional Phase 2 data showing remlifanserin efficacy signal in Alzheimer's psychosis
ACAD•Acadia reported additional Phase 2 results for remlifanserin in Alzheimer's disease psychosis. The 60 mg dose showed benefits across psychosis measures but narrowly missed the primary endpoint, while a key secondary endpoint achieved nominal significance.
1. Phase 2 findings
Acadia Pharmaceuticals presented additional RADIANT results at the 2026 CTAD conference. The once-daily 60 mg dose showed consistent benefits across psychosis measures but narrowly missed the primary endpoint; a key secondary endpoint achieved nominal significance. The 30 mg dose showed minimal benefit over placebo, and safety findings were consistent with earlier results, with no negative impact on cognition or motor symptoms versus placebo.
2. Phase 3 development
Phase 3 development for Alzheimer's disease psychosis continues based on the Phase 2 findings.




